Edward M. Kaye, M.D
Principal executive officer pay for Edward M. Kaye, M.D, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Stoke Therapeutics, Inc. (STOK) FY2023–FY2025
Aligned: paid up as stock roseCAP $1,117,069→$10,570,860 while $100 invested went $56.99→$343.88
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $3.5M | $1.1M |
| FY2024 | $5.6M | $7.5M |
| FY2025 | $3.2M | $10.6M |
The company's "$100 invested" index ran $56.99 at FY2023 → $343.88 by FY2025 — an annualized return of 145.6%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 145.6%/yr at STOK ( FY2023–FY2025). See the CEO track-record ranking for context.